8DA59514-8B25-493E-B226-818F2521B5D5
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 7.588699080157687
- age_years
- 56
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.619
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.571
- TNFA_SIGNALING_VIA_NFKB+0.560
- OXIDATIVE_PHOSPHORYLATION+0.558
- E2F_TARGETS+0.547
- MYC_TARGETS_V2+0.531
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.530
- DNA_REPAIR+0.513
- INTERFERON_ALPHA_RESPONSE+0.505
- IL6_JAK_STAT3_SIGNALING+0.496
Top 10 suppressed
- KRAS_SIGNALING_DN-0.335
- MITOTIC_SPINDLE-0.160
- SPERMATOGENESIS-0.143
- MYOGENESIS-0.095
- HEDGEHOG_SIGNALING-0.061
- HEME_METABOLISM-0.055
- BILE_ACID_METABOLISM-0.031
- UV_RESPONSE_DN-0.031
- APICAL_SURFACE-0.006
- ESTROGEN_RESPONSE_EARLY-0.001
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 1B326CC6-3916-4D1D-A238-7B3C42F3E6C6 | — | — | 0.970 |
| 2 | 9BB56866-4E99-4E8A-A63F-2D4801558F14 | — | — | 0.969 |
| 3 | 3027792F-79B6-4729-9452-C4A72A7C4686 | — | — | 0.969 |
| 4 | 788A8487-6A02-4BF5-8E84-16BE5D92BF0F | — | — | 0.967 |
| 5 | 53B31ABD-AD68-4A44-A525-23FD413115D5 | — | — | 0.966 |
| 6 | SRR934883 | — | — | 0.966 |
| 7 | 4A54E284-9902-4E4C-A5BC-1BF144106EA3 | — | — | 0.964 |
| 8 | CC9815B3-88D0-4376-B96F-B979E1FBD0C7 | — | — | 0.963 |
| 9 | 5063882F-6377-4976-BB48-7275D46C44E6 | — | — | 0.962 |
| 10 | AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE | — | — | 0.962 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.619 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.571 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.560 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.558 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.547 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.531 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.530 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.513 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.505 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.496 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.496 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.485 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.482 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.467 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.457 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.455 | Inavolisib | — uncovered |
| APOPTOSIS | 0.444 | Idelalisib | — uncovered |
| HYPOXIA | 0.443 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.424 | Inavolisib | — uncovered |
| COAGULATION | 0.418 | Binimetinib | — uncovered |